Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has received a EUR 1.2 million grant from VLAIO, the Flanders organization for Innovation & Entrepreneurship, for the development of the highly innovative GeneFusion Assay on its easy, rapid molecular and fully automated diagnostics platform Idylla™.
The post Biocartis Receives EUR 1.2 million Grant for Development of Highly Innovative Idylla™ GeneFusion Assay appeared first on Pharma Mirror Magazine.
